Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β2-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 µg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV1. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV1 increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.

Keywords:
Inhaled corticosteroid, Long-acting inhaled β2-agonist, Severe asthma, Theophylline
1.
Global Initiative for Asthma: Global strategy for asthma management and prevention. National Institutes of Health: National Heart, Lung, and Blood Institute. Bethesda, National Institutes of Health, 2002.
2.
O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–1397.
3.
Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405–1411.
4.
Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813–818.
5.
Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99:8921–8926.
6.
Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412–1418.
7.
Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ: Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995;151:1907–1914.
8.
Kraft M, Wenzel SE, Bettinger CM, Martin RJ: The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997;111:1249–1254.
9.
Thirstrup S, Nielsen-Kudsk F, Dahl R: In vitro studies on the interactions of β2-adrenoceptor agonists, methylxanthines, Ca2+-channel blockers, K+-channel openers and other airway smooth muscle relaxants in isolated guinea-pig trachea. Eur J Pharmacol 1997;326:191–200.
10.
Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijarvi A, et al: Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700–705.
11.
van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Kerrebijn KF, Pocock SJ: Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group. Eur Respir J 1994;7:63–68.
12.
Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH: Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994;150:1006–1011.
13.
Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJ: Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583–2593.
14.
Lindqvist A, Karjalainen EM, Laitinen LA, Kava T, Altraja A, Pulkkinen M, Halme M, Laitinen A: Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol 2003;112:23–28.
15.
Jenne JW, Yeoh HC, Shaughnessy TK, Hur K: Theophylline produces over-additive relaxation of canine tracheal smooth muscle when combined with β-agonists: the dose-response relationship. Pulm Pharmacol 1992;5:239–249.
16.
Laursen LC, Taudorf E, Gnosspelius Y, Gymose E, Weeke B: Long-term oral therapy of asthma with terbutaline and theophylline, alone and combined. Eur J Respir Dis 1985;66:82–90.
17.
Rivington RN, Boulet LP, Cote J, Kreisman H, Small DI, Alexander M, Day A, Harsanyi Z, Darke AC: Efficacy of uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995;151:325–332.
18.
Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–965.
19.
ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K: Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661–1670.
20.
Cheung D, Wever AM, de GJ, de GC, Steen H, Sterk PJ: Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. Am J Respir Crit Care Med 1998;158:792–796.
21.
Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE: Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994;49:771–774.
22.
Shrewsbury S, Hallett C: Salmeterol 100 microg: an analysis of its tolerability in single- and chronic-dose studies. Ann Allergy Asthma Immunol 2001;87:465–473.
23.
Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE: Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000;55:650–656.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.